SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far
Respiratory infections are the most common and most frequent diseases, especially in children and the elderly, characterized by a clear seasonality and with an incidence that usually tends to decrease with increasing age. These infections often resolve spontaneously, usually without the need for ant...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/12/2087 |
| _version_ | 1797456687760670720 |
|---|---|
| author | Carmelo Biondo Angelina Midiri Elisabetta Gerace Sebastiana Zummo Giuseppe Mancuso |
| author_facet | Carmelo Biondo Angelina Midiri Elisabetta Gerace Sebastiana Zummo Giuseppe Mancuso |
| author_sort | Carmelo Biondo |
| collection | DOAJ |
| description | Respiratory infections are the most common and most frequent diseases, especially in children and the elderly, characterized by a clear seasonality and with an incidence that usually tends to decrease with increasing age. These infections often resolve spontaneously, usually without the need for antibiotic treatment and/or with the possible use of symptomatic treatments aimed at reducing overproduction of mucus and decreasing coughing. However, when these infections occur in patients with weakened immune systems and/or underlying health conditions, their impact can become dramatic and in some cases life threatening. The rapid worldwide spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has caused concern for everyone, becoming especially important for individuals with underlying lung diseases, such as CF patients, who have always paid close attention to implementing protective strategies to avoid infection. However, adult and pediatric CF patients contract coronavirus infection like everyone else. In addition, although numerous studies were published during the first wave of the pandemic on the risk for patients with cystic fibrosis (CF) to develop severe manifestations when infected with SARS-CoV-2, to date, a high risk has been found only for patients with poorer lung function and post-transplant status. In terms of preventive measures, vaccination remains key. The best protection for these patients is to strengthen preventive measures, such as social distancing and the use of masks. In this review, we aim to summarize and discuss recent advances in understanding the susceptibility of CF individuals to SARS-CoV-2 infection. |
| first_indexed | 2024-03-09T16:11:25Z |
| format | Article |
| id | doaj.art-d932553fb9d946a6aaa4064ddf62e5b1 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T16:11:25Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-d932553fb9d946a6aaa4064ddf62e5b12023-11-24T16:13:19ZengMDPI AGLife2075-17292022-12-011212208710.3390/life12122087SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So FarCarmelo Biondo0Angelina Midiri1Elisabetta Gerace2Sebastiana Zummo3Giuseppe Mancuso4Department of Human Pathology, University of Messina, 98125 Messina, ItalyDepartment of Human Pathology, University of Messina, 98125 Messina, ItalyASP (Azienda Sanitaria Provinciale), 90141 Palermo, ItalyDepartment of Human Pathology, University of Messina, 98125 Messina, ItalyDepartment of Human Pathology, University of Messina, 98125 Messina, ItalyRespiratory infections are the most common and most frequent diseases, especially in children and the elderly, characterized by a clear seasonality and with an incidence that usually tends to decrease with increasing age. These infections often resolve spontaneously, usually without the need for antibiotic treatment and/or with the possible use of symptomatic treatments aimed at reducing overproduction of mucus and decreasing coughing. However, when these infections occur in patients with weakened immune systems and/or underlying health conditions, their impact can become dramatic and in some cases life threatening. The rapid worldwide spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has caused concern for everyone, becoming especially important for individuals with underlying lung diseases, such as CF patients, who have always paid close attention to implementing protective strategies to avoid infection. However, adult and pediatric CF patients contract coronavirus infection like everyone else. In addition, although numerous studies were published during the first wave of the pandemic on the risk for patients with cystic fibrosis (CF) to develop severe manifestations when infected with SARS-CoV-2, to date, a high risk has been found only for patients with poorer lung function and post-transplant status. In terms of preventive measures, vaccination remains key. The best protection for these patients is to strengthen preventive measures, such as social distancing and the use of masks. In this review, we aim to summarize and discuss recent advances in understanding the susceptibility of CF individuals to SARS-CoV-2 infection.https://www.mdpi.com/2075-1729/12/12/2087cystic fibrosisviral infectionsCOVID-19 |
| spellingShingle | Carmelo Biondo Angelina Midiri Elisabetta Gerace Sebastiana Zummo Giuseppe Mancuso SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far Life cystic fibrosis viral infections COVID-19 |
| title | SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far |
| title_full | SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far |
| title_fullStr | SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far |
| title_full_unstemmed | SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far |
| title_short | SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far |
| title_sort | sars cov 2 infection in patients with cystic fibrosis what we know so far |
| topic | cystic fibrosis viral infections COVID-19 |
| url | https://www.mdpi.com/2075-1729/12/12/2087 |
| work_keys_str_mv | AT carmelobiondo sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar AT angelinamidiri sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar AT elisabettagerace sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar AT sebastianazummo sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar AT giuseppemancuso sarscov2infectioninpatientswithcysticfibrosiswhatweknowsofar |